Get the Stockscreener App
11.42
5.46%
-0.66
Amylyx Pharmaceuticals Inc stock is traded at $11.42, with a volume of 2.12M.
It is down -5.46% in the last 24 hours and down -16.95% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$12.08
Open:
$12
24h Volume:
2.12M
Relative Volume:
1.33
Market Cap:
$1.25B
Revenue:
$-249.00K
Net Income/Loss:
$-187.60M
P/E Ratio:
-4.568
EPS:
-2.5
Net Cash Flow:
$-201.88M
1W Performance:
-7.38%
1M Performance:
-16.95%
6M Performance:
+73.82%
1Y Performance:
+192.07%
1-Day Range:
$11.06
$12.11
1-Week Range:
$11.06
$12.57
52-Week Range:
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
11.42 | 1.33B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 7.2%Time to Sell? - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Guidance Update: What margin trends mean for Amylyx Pharmaceuticals Inc stockPortfolio Return Summary & Daily Oversold Bounce Ideas - moha.gov.vn
Hedge Fund and Insider Trading News: Ken Griffin, Ray Dalio, Warren Buffett, Toms Capital, Ken Fisher, Pershing Square, Amylyx Pharmaceuticals Inc (AMLX), NVIDIA Corp (NVDA), and More - Insider Monkey
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase - Quiver Quantitative
Amylyx announces proposed public offering of common stock - MSN
How Investors Are Reacting To Amylyx Pharmaceuticals (AMLX) Early AMX0114 Safety Data And Insider Buying - Sahm
Amylyx Pharma director Firestone buys $100k in AMLX stock By Investing.com - Investing.com Canada
Amylyx Pharma director Firestone buys $100k in AMLX stock - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Acquires $100,845.00 in Stock - MarketBeat
Amylyx Pharmaceuticals Director Karen Firestone Acquires 8,100 Shares - TradingView — Track All Markets
Will Amylyx Pharmaceuticals Inc. stock deliver long term returnsEvening Star Patterns & Free Rapid Return Acceleration - Bollywood Helpline
How Amylyx Pharmaceuticals Inc. stock trades before earningsLayoff News & Verified Momentum Watchlists - Улправда
Will Amylyx Pharmaceuticals Inc. stock recover faster than peers2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
Bank of America Securities Keeps Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Will Amylyx Pharmaceuticals Inc. stock return to pre crisis levelsBull Run & Expert Approved Momentum Trade Ideas - Улправда
Will Amylyx Pharmaceuticals Inc. stock benefit from sector rotation2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Is Amylyx Pharmaceuticals Inc. stock recession proofTrade Risk Report & High Conviction Buy Zone Alerts - DonanımHaber
What margin trends mean for Amylyx Pharmaceuticals Inc. stockMarket Activity Summary & High Conviction Buy Zone Picks - DonanımHaber
Is Amylyx Pharmaceuticals Inc. stock trading at a premium valuationEarnings Summary Report & Weekly Sector Rotation Insights - ulpravda.ru
AMLX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class ActionAMLX - TMX Newsfile
Amylyx Pharmaceuticals Earnings Notes - Trefis
TFG Asset Management GP Ltd Makes New $1.40 Million Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
683 Capital Management LLC Has $13.85 Million Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
ALS medication AMX0114 shows safety, moves to 2nd trial group - ALS News Today
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 12.96% to 20.74 - MSN
Amylyx pins its next hopes on a niche drug in the obesity space - Pharma Voice
Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge? - Sahm
Amylyx presents safety outcomes of AMX0114 in LUMINA study - MSN
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? - Nasdaq
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Mizuho Securities - The Globe and Mail
Rare Disease Leaders Call for Regulatory Consistency After Chaotic Year - BioSpace
Amylyx’s ALS drug AMX0114 shows positive early safety data By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Positive Buy Rating for Amylyx Pharmaceuticals Based on Promising Phase I LUMINA Study Results and Strategic Advancements - TipRanks
Presentation at MNDA: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and Its Application in the Phase 1 LUMINA Trial (dae63b) - marketscreener.com
Amylyx’s ALS drug AMX0114 shows positive early safety data - Investing.com India
Amylyx Pharmaceuticals announces new safety and tolerability cohort 1 data of amx0114 - marketscreener.com
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial - Business Wire
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Increased by Saturn V Capital Management LP - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Lifted by Alpha Wave Global LP - MarketBeat
Can Amylyx Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Camille Bedrosian Sells 6,580 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Geode Capital Management LLC Acquires 886,252 Shares of Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Top Executive Makes Significant Stock Sale at Amylyx Pharmaceuticals - TipRanks
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 04 - marketscreener.com
Amylyx Pharmaceuticals CMO Sells Shares to Cover Tax Obligations - TradingView
Officer Bedrosian Surrenders 6,580 Of Amylyx Pharmaceuticals Inc [AMLX] - TradingView
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? - Yahoo Finance
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bedrosian Camille L | Chief Medical Officer |
Dec 01 '25 |
Sale |
14.35 |
6,580 |
94,418 |
175,756 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):